Modality
Degrader
MOA
HPK1i
Target
MET
Pathway
mTOR
MCCNSCLCNMOSD
Development Pipeline
Preclinical
~Nov 2014
→ ~Feb 2016
Phase 1
~May 2016
→ ~Aug 2017
Phase 2
~Nov 2017
→ ~Feb 2019
Phase 3
May 2019
→ Feb 2030
Phase 3Current
NCT03110308
1,005 pts·NMOSD
2023-06→2026-07·Terminated
NCT04313799
113 pts·MCC
2020-07→2030-02·Terminated
NCT07678048
2,931 pts·NMOSD
2019-05→TBD·Active
4,049 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-07-013mo awayPh3 Readout· NMOSD
2026-10-177mo awayEMA Filing· NSCLC
2030-02-023.8y awayPh3 Readout· MCC
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P3
Active
P3
Termina…
P3
Termina…
Catalysts
Ph3 Readout
2026-07-01 · 3mo away
NMOSD
EMA Filing
2026-10-17 · 7mo away
NSCLC
Ph3 Readout
2030-02-02 · 3.8y away
MCC
ActiveTerminated|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03110308 | Phase 3 | NMOSD | Terminated | 1005 | ACR20 |
| NCT04313799 | Phase 3 | MCC | Terminated | 113 | LiverFat |
| NCT07678048 | Phase 3 | NMOSD | Active | 2931 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 | |
| RVM-274 | Revolution Medicines | Phase 3 | MET | |
| COR-9566 | Corcept | Approved | TYK2 |